1. Home
  2. TALK vs KALV Comparison

TALK vs KALV Comparison

Compare TALK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$5.13

Market Cap

788.5M

Sector

Health Care

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$17.02

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
KALV
Founded
2012
N/A
Country
United States
United States
Employees
521
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.5M
757.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TALK
KALV
Price
$5.13
$17.02
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$6.42
$30.00
AVG Volume (30 Days)
5.8M
761.7K
Earning Date
05-05-2026
05-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$26.02
N/A
Revenue Next Year
$21.24
N/A
P/E Ratio
$155.55
N/A
Revenue Growth
N/A
495.66
52 Week Low
$2.22
$9.83
52 Week High
$5.19
$19.00

Technical Indicators

Market Signals
Indicator
TALK
KALV
Relative Strength Index (RSI) 66.17 56.35
Support Level $4.59 $14.59
Resistance Level $5.19 $17.30
Average True Range (ATR) 0.09 1.10
MACD -0.02 -0.04
Stochastic Oscillator 90.02 57.48

Price Performance

Historical Comparison
TALK
KALV

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: